PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsEmpagliflozin
Jardiance(empagliflozin)
Glyxambi, Jardiance, Synjardy, Trijardy (empagliflozin) is a small molecule pharmaceutical. Empagliflozin was first approved as Jardiance on 2014-05-22. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat chronic renal insufficiency, heart failure, and type 2 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2. In addition, it is known to target sodium/glucose cotransporter 1.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Jardiance (discontinued: Empagliflozin)
Combinations
Glyxambi, Synjardy, Trijardy (discontinued: Empagliflozin metformin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Empagliflozin
+
Linagliptin
Tradename
Company
Number
Date
Products
GLYXAMBIBoehringer IngelheimN-206073 RX2015-01-30
2 products, RLD, RS
Empagliflozin
Tradename
Company
Number
Date
Products
JARDIANCEBoehringer IngelheimN-204629 RX2014-08-01
2 products, RLD, RS
Empagliflozin
+
Metformin hydrochloride
Tradename
Company
Number
Date
Products
SYNJARDYBoehringer IngelheimN-206111 RX2015-08-26
4 products, RLD, RS
SYNJARDY XRBoehringer IngelheimN-208658 RX2016-12-09
4 products, RLD, RS
Empagliflozin
+
Linagliptin
+
Metformin hydrochloride
Tradename
Company
Number
Date
Products
TRIJARDY XRBoehringer IngelheimN-212614 RX2020-01-27
4 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
glyxambiNew Drug Application2025-10-09
jardianceNew Drug Application2025-12-12
synjardyNew Drug Application2025-10-30
synjardy synjardyNew Drug Application2023-06-26
trijardy xrNew Drug Application2025-10-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
Expiration
Code
EMPAGLIFLOZIN, JARDIANCE, BOEHRINGER INGELHEIM
2025-08-24PED
2025-02-24M-82
2025-02-18PED
2024-08-18I-869
EMPAGLIFLOZIN / LINAGLIPTIN, GLYXAMBI, BOEHRINGER INGELHEIM
2023-03-30M-252
Patent Expiration
Patent
Expires
Flag
FDA Information
Empagliflozin, Jardiance, Boehringer Ingelheim
99499982034-06-11U-2290, U-2731
99499972034-05-17U-2292, U-3199, U-3325, U-3532, U-3533
102586372034-04-03U-2290, U-2731
110903232034-04-03U-3191, U-3192, U-3193
85519572029-10-14U-1651, U-2730
75794492028-08-01DP
77139382027-04-15DS, DP
Empagliflozin / Linagliptin / Metformin Hydrochloride, Trijardy Xr, Boehringer Ingelheim
105961202032-03-07DPU-2775, U-2776, U-2790, U-2792
115648862032-03-07DPU-3531
104061722030-06-15DPU-2733
91557052030-05-21DP
94150162029-04-02DP
100223792029-04-02DPU-2732
Empagliflozin / Metformin Hydrochloride, Synjardy, Boehringer Ingelheim
106104892030-09-30DP
Empagliflozin / Linagliptin, Glyxambi, Boehringer Ingelheim
86739272027-05-04U-1652
91738592027-05-04DPU-1772
110335522027-05-04DP
88838052025-11-26DP
74079552025-05-02DS, DP
81196482023-08-12U-1651, U-1652
81785412023-08-12DPU-1652, U-1653, U-1654
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD19: Linagliptin and empagliflozin
— A10BD20: Metformin and empagliflozin
— A10BD27: Metformin, linagliptin and empagliflozin
— A10BK: Sodium-glucose co-transporter 2 (sglt2) inhibitors
— A10BK03: Empagliflozin
HCPCS
No data
Clinical
Clinical Trials
568 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E113221485966225
Diabetes mellitusD003920EFO_0000400E08-E131622435027158
Heart failureD006333EFO_0003144I5051720231780
Healthy volunteers/patients———531—2—56
Kidney diseasesD007674EFO_0003086N0828413835
Chronic renal insufficiencyD051436—N1821049327
Type 1 diabetes mellitusD003922EFO_0001359E107447224
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.81—4210723
Cardiovascular diseasesD002318EFO_0000319I982—16716
Fatty liverD005234EFO_0003934——416516
Show 78 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfarctionD007238EFO_0009463———3—25
StrokeD020521EFO_0000712I63.9—22——3
PharmacokineticsD010599——1—1—13
Kidney calculiD007669EFO_0004253N20111——3
Ischemic strokeD000083242————1—12
Right ventricular dysfunctionD018497———11——2
Congenital generalized lipodystrophyD052497————2——2
Lipoatrophic diabetes mellitusD003923EFO_0007346———2——2
Acute liver failureD017114———11——2
Inferior wall myocardial infarctionD056989EFO_1000983———1—12
Show 25 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeutropeniaD009503—D7012———3
Glycogen storage disease type iD005953Orphanet_364E74.01—3———3
Glycogen storage diseaseD006008—E74.0—2——13
Body weightD001835EFO_0004338—12———3
Cognitive dysfunctionD060825—G31.84—1——23
Pulmonary arterial hypertensionD000081029——12———3
Breast neoplasmsD001943EFO_0003869C5012———2
HypersensitivityD006967EFO_0003785T78.4011———2
NephritisD009393—N0512———2
DiseaseD004194EFO_0000408R69—1——12
Show 27 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
KetosisD007662—R82.42———24
Wounds and injuriesD014947—T14.81———12
Renal dialysisD006435EFO_0010690Z99.21———12
Pharmacological phenomenaD000069437——1————1
Hepatic insufficiencyD048550——1————1
Crohn diseaseD003424EFO_0000384K501————1
Inflammatory bowel diseasesD015212EFO_0003767—1————1
Carbohydrate metabolismD050260——1————1
DialysisD003956——1————1
EpilepsyD004827EFO_0000474G40.91————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic ketoacidosisD016883EFO_1000897—————33
InfectionsD007239EFO_0000544—————22
Urinary tract infectionsD014552EFO_0003103N39.0————22
SepsisD018805EFO_0001420A41.9————22
Communicable diseasesD003141——————11
Body weight changesD001836——————11
Diabetes insipidusD003919—E23.2————11
Bariatric surgeryD050110——————11
AcromegalyD000172——————11
Reperfusion injuryD015427——————11
Show 14 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEmpagliflozin
INNempagliflozin
Description
Empagliflozin is a C-glycosyl compound consisting of a beta-glucosyl residue having a (4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl group at the anomeric centre. A sodium-glucose co-transporter 2 inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It has a role as a sodium-glucose transport protein subtype 2 inhibitor and a hypoglycemic agent. It is a C-glycosyl compound, an aromatic ether, a tetrahydrofuryl ether and a member of monochlorobenzenes.
Classification
Small molecule
Drug classphlorozin derivatives, phenolic glycosides
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O
Identifiers
PDB—
CAS-ID864070-44-0
RxCUI—
ChEMBL IDCHEMBL2107830
ChEBI ID82720
PubChem CID11949646
DrugBankDB09038
UNII IDHDC1R2M35U (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
ACADS
ACADS
Organism
Homo sapiens
Gene name
ACADS
Gene synonyms
NCBI Gene ID
35
Protein name
short-chain specific acyl-CoA dehydrogenase, mitochondrial
Protein synonyms
acyl-CoA dehydrogenase, C-2 to C-3 short chain, acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain, Butyryl-CoA dehydrogenase, epididymis secretory sperm binding protein, mitochondrial short-chain specific acyl-CoA dehydrogenase, unsaturated acyl-CoA reductase
Uniprot ID
P78331
Mouse ortholog
Acads (11409)
short-chain specific acyl-CoA dehydrogenase, mitochondrial (Q91W85)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Jardiance – Eli Lilly
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Empagliflozin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Empagliflozin
+
Metformin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 18,146 documents
View more details
Safety
Black-box Warning
Black-box warning for: Synjardy, Synjardy synjardy, Trijardy xr
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
41,900 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use